4-Bromobenzo[b]thiophene CAS 5118-13-8 Purity >97.0% (GC) Brexpiprazole Intermediate Manufacturer

4-Bromobenzo[b]thiophene (CAS: 5118-13-8) is used as a useful synthetic intermediate, and it is mainly exported to India, North America, Korea, Japanese, and Europe. 4-Bromobenzo[b]thiophene is an intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression. Brexpiprazole has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD). Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic. Brexpiprazole is a dopamine D2 receptor partial agonist and has been described as a "serotonin-dopamine activity modulator" (SDAM). Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor of Otsuka's top-selling atypical antipsychotic aripiprazole (Abilify).